The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. [electronic resource]
Producer: 20161213Description: 106-17 p. digitalISSN:- 1468-1293
- Adult
- Anti-HIV Agents -- therapeutic use
- Antiretroviral Therapy, Highly Active
- Atazanavir Sulfate -- therapeutic use
- Biomarkers -- blood
- Bone Density -- drug effects
- CD4 Lymphocyte Count
- Dideoxynucleosides -- therapeutic use
- Drug Combinations
- Drug Substitution -- methods
- Female
- HIV Infections -- blood
- Humans
- Kidney -- drug effects
- Lamivudine -- therapeutic use
- Lipids -- blood
- Male
- Middle Aged
- RNA, Viral -- blood
- Ritonavir -- adverse effects
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.